Search Results 691-700 of 17090 for egfr

  1. Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy - Mayo Clinic

    ... [eGFR] < 45 ml/min/1.73 m^2). [Gillmore 2018]. Current or future participation in another investigational device or drug study, scheduled to occur during ...

  2. Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects - Mayo Clinic

    Normal serum potassium and estimated glomerular filtration rate (eGFR) > 60 ml/minute; Baseline systolic BP ≥ 110 mmHg; No known hypersensitivity to ...

  3. Investigational Trial To Evaluate XC001 Delivered Via An Cardiac Catheter In Subjects With Chronic Angina. - Mayo Clinic

    ... (eGFR) \< 30 mL/min/1.73 m2 6. Diabetic with current glycosylated hemoglobin (HbA1c) \> 9.5% or active proliferative diabetic retinopathy. 7. Documented ...

  4. The Effect of Glutamine on Intestinal Permeability and Symptoms in Patients with Functional Dyspepsia in a Randomized, Placebo-Controlled Trial - Mayo Clinic

    Estimated Glomerular Filtration Rate (eGFR) of < 60 mL/min/BSA. Diagnosed with galactosemia. Pregnant or breastfeeding women. Patients with documented or ...

  5. A Study to Evaluate AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment - Mayo Clinic

    - eGFR <30 mL/minute/1.73 m^2. Note: Other protocol defined Inclusion/Exclusion criteria may apply. Eligibility last updated 12/8/22. Questions regarding ...

  6. A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC - Mayo Clinic

    Documented EGFR and ALK wild-type status (local or central). Participants must have not progressed following definitive, platinum-based, concurrent ...

  7. Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation (VISTA) - Mayo Clinic

    Significant renal dysfunction (eGFR<30 ml/min/1.73m2) or on dialysis; End-stage liver disease (MELD > 11 / CHILD class C); Bleeding requiring transfusion ...

  8. A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer - Mayo Clinic

    Prior treatment with any anti-HER2 and/or anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor including pyrotinib, lapatinib, tucatinib ...

  9. Focal segmental glomerulosclerosis (FSGS) - Doctors and departments - Mayo Clinic

    Departments and specialties. Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, ...

  10. A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Subject must have an eGFR ≥ 30 mL/min as estimated by the MDRD formula. Subject must have total bilirubin ≤ 1.5 × upper limit of normal (ULN; except if ...